国际医药卫生导报2024,Vol.30Issue(6) :1025-1027.DOI:10.3760/cma.j.issn.1007-1245.2024.06.030

特瑞普利单抗治疗转移性恶性黑色素瘤1例

A case of metastatic malignant melanoma treated with toripalimab

徐兰 叶刚
国际医药卫生导报2024,Vol.30Issue(6) :1025-1027.DOI:10.3760/cma.j.issn.1007-1245.2024.06.030

特瑞普利单抗治疗转移性恶性黑色素瘤1例

A case of metastatic malignant melanoma treated with toripalimab

徐兰 1叶刚1
扫码查看

作者信息

  • 1. 暨南大学附属第一医院消化内科,广州 510630
  • 折叠

摘要

恶性黑色素瘤发病率低,致死率高、生存期短,早期以手术治疗为主,晚期多予以应用化学药物治疗,但有效率不高.免疫治疗在多种恶性肿瘤治疗中取得进阶性、突破性发展,同时也在临床中被证实可延长恶性黑色素瘤患者的生存时间.本文分享暨南大学附属第一医院1例特瑞普利单抗治疗转移性恶性黑色素瘤并获得较佳疗效的病例.

Abstract

The incidence of malignant melanoma is low,the mortality is high,and the survival time is short.In the early stage,surgery is the main treatment;in the late stage,chemical drugs are mostly used,but the effective rate is not high.Immunotherapy has achieved advanced and breakthrough development in the treatment of a variety of malignant tumors,and has also been proved to prolong the survival time of malignant melanoma patients in clinical practice.This article is to share a case of metastatic malignant melanoma treated with toripalimab who has achieved good efficacy in the First Affiliated Hospital of Jinan University.

关键词

恶性黑色素瘤/特瑞普利单抗/免疫治疗

Key words

Malignant melanoma/Toripalimab/Immunotherapy

引用本文复制引用

基金项目

广东省基础与应用基础研究基金(2023A1515011617)

出版年

2024
国际医药卫生导报
中华医学会,国际医药卫生导报社

国际医药卫生导报

影响因子:0.781
ISSN:1007-1245
参考文献量21
段落导航相关论文